![Matthew Baker](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Matthew Baker
Director/Board Member at
FUSION ANTIBODIES PLC
Net worth: 50 338 $ as of 30/05/2026
Profile
Matthew Paul Baker was the founder of Abzena Ltd., founded in 2001, where the title held was Chief Scientific Officer from 2013 to 2016.
Dr. Baker was the founder of Abzena (Cambridge) Ltd., founded in 2004, where the titles held were CEO, Director & Chief Scientific Officer from 2004 to 2016.
Dr. Baker is currently Chief Executive Officer at Laigo Bio BV since 2025 and Independent Non-Executive Director at Fusion Antibodies Plc since 2022.
Former jobs include Chief Executive Officer at NeoPhore Ltd. from 2020 to 2024, Non-Executive Director at Mercia Asset Management Plc, Non-Executive Director at Oxford Genetics Ltd. from 2016 to 2021, Executive Vice President-Biologics Discovery at Biovation Ltd., and Chief Scientific Officer at PolyTherics Ltd. Education includes a doctorate from the University of Birmingham.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 10/07/2025 | 292,902 ( 0.23% ) | 50 338 $ | 30/05/2026 |
Matthew Baker active positions
| Companies | Position | Start |
|---|---|---|
| FUSION ANTIBODIES PLC | Director/Board Member | 28/02/2022 |
Former positions of Matthew Baker
| Companies | Position | End |
|---|---|---|
NeoPhore Ltd.
 NeoPhore Ltd. Miscellaneous Commercial ServicesCommercial Services Engages in discovery and development of small molecules inhibitors to treat cancer | Chief Executive Officer | 12/06/2024 |
Oxford Genetics Ltd.
 Oxford Genetics Ltd. BiotechnologyHealth Technology Develops cell and gene therapies | Director/Board Member | 31/12/2020 |
| ABZENA PLC | Founder | 30/09/2016 |
Abzena (Cambridge) Ltd.
 Abzena (Cambridge) Ltd. Miscellaneous Commercial ServicesCommercial Services Provides antibody engineering and immunogenicity screening services | Chief Executive Officer | 31/12/2015 |
| MERCIA ASSET MANAGEMENT PLC | Director/Board Member | - |
Training of Matthew Baker
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
18
1st degree connections
9
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 9 |
|---|---|
Biovation Ltd.
 Biovation Ltd. Miscellaneous Commercial ServicesCommercial Services Develops proprietary pharmaceutical and diagnostic agents | Commercial Services |
University of Birmingham
 University of Birmingham Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Fusion Antibodies Plc
 Fusion Antibodies Plc Medical/Nursing ServicesHealth Services Develops antibody-based therapeutic products | Health Services |
PolyTherics Ltd.
 PolyTherics Ltd. Pharmaceuticals: MajorHealth Technology Develops biomedical polymers for therapeutic applications | Health Technology |
Abzena (Cambridge) Ltd.
Abzena (Cambridge) Ltd. Miscellaneous Commercial ServicesCommercial Services Provides antibody engineering and immunogenicity screening services | Commercial Services |
Oxford Genetics Ltd.
Oxford Genetics Ltd. BiotechnologyHealth Technology Develops cell and gene therapies | Health Technology |
Abzena Ltd.
 Abzena Ltd. BiotechnologyHealth Technology Engages in discovery, development and manufactures biologics drugs | Health Technology |
Mercia Asset Management Plc
 Mercia Asset Management Plc Financial ConglomeratesFinance Provides private equity and venture capital fund management services | Finance |
NeoPhore Ltd.
NeoPhore Ltd. Miscellaneous Commercial ServicesCommercial Services Engages in discovery and development of small molecules inhibitors to treat cancer | Commercial Services |
- Stock Market
- Insiders
- Matthew Baker
